It appears that drugs targeting STAT3/p-STAT3/RPS27a combining with TKI might represent a novel therapy strategy in some patients with TKI resistant CML. The gene discussed is STAT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.